Vir Biotechnology, Inc. (Nasdaq: VIR) announced that they will be providing a corporate update and reporting financial results for the first quarter of 2024, ending on March 31, 2024, on May 2, 2024. The company will be hosting a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The information will be shared through a press release after the market closes and will be accessible on the Vir website under Press Releases in the Investors section at www.vir.bio. Participants can join the conference call via webcast on the Events & Presentations page on Vir’s website or by dialing the U.S. toll-free number (888) 800-8770 or international +1 (646) 307-1953, Conference ID: 756877. A recorded version of the call will be available on the website approximately two hours after the event and will be archived there for 30 days.

Vir Biotechnology, Inc. is an immunology company that focuses on empowering the immune system to treat and prevent infectious diseases and other serious conditions. They are dedicated to transforming lives through their research and development efforts. The company has two technology platforms that aim to modulate the immune system by leveraging natural immune processes. Their current clinical development pipeline includes product candidates targeting hepatitis delta and hepatitis B viruses, as well as human immunodeficiency virus. Additionally, they have various preclinical candidates in their pipeline, such as those targeting influenza A and B, COVID-19, RSV/MPV, and HPV. Vir regularly updates investors with important information on its website.

For media inquiries, please contact Carly Scaduto, Senior Director of External Communication, at cscaduto@vir.bio or +1 314-368-5189. For investor relations, reach out to Richard Lepke, Senior Director of Investor Relations, at rlepke@vir.bio or +1 978-973-9986.